Home・Aktien・Coherus Oncology Inc

Coherus Oncology Inc

Geschlossen

BrancheGesundheitswesen

1.14 -4.2

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.17

Max

1.19

Schlüsselkennzahlen
By Trading Economics
Einkommen	-21M -59M
Verkäufe	2M 14M
KGV Branchendurchschnitt	3.509 57.002
EPS	-0.22
Gewinnspanne	-412.092
Angestellte	144
EBITDA	2.8M -31M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+545.83% upside

Dividenden
By Acuity
Nächstes Ergebnis	5. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-31M 192M
Vorheriger Eröffnungskurs	5.34
Vorheriger Schlusskurs	1.14

Nachrichtenstimmung

By Acuity

50%

146 / 340 Ranking in Healthcare

Coherus Oncology Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Coherus Oncology Inc Prognose

Kursziel

By TipRanks

545.83% Vorteil

12-Monats-Prognose

Durchschnitt 7.75 USD 545.83%

Hoch 10 USD

Tief 4 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Coherus Oncology Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Coherus Oncology Inc – Dist abgegeben haben.

Stimmung

By Acuity

146 / 340 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.